Bridgeway Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Bridgeway Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$161K	Sell	14,000 -18,691	-57%	-$149K	﹤0.01%	1097
2026 Q1	$155K	Hold	32,691	–	–	﹤0.01%	1072
2025 Q4	$591K	Buy	32,691 +18,691	+134%	+$279K	0.01%	788
2025 Q3	$201K	Hold	14,000	–	–	﹤0.01%	1009
2025 Q2	$108K	Hold	14,000	–	–	﹤0.01%	1060
2025 Q1	$83.2K	Hold	14,000	–	–	﹤0.01%	1069
2024 Q4	$186K	Hold	14,000	–	–	﹤0.01%	1027
2024 Q3	$114K	Hold	14,000	–	–	﹤0.01%	1147
2024 Q2	$119K	Buy	+14,000	New	+$211K	﹤0.01%	1148

Other funds holding ATRA

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Bridgeway Capital Management's ATRA Position: Q2 2026 in Review

Bridgeway Capital Management reduced its Atara Biotherapeutics (ATRA) stake by 57% in Q2 2026, selling an estimated $149K and leaving 14,000 shares worth $161K. The position accounts for ﹤0.01% of the portfolio, ranked #1097.

Bridgeway Capital Management first reported a position in ATRA in Q2 2024 and has held it in 9 quarters since. The position peaked at $591K in Q4 2025. 36 funds tracked by Wall St. Rank hold ATRA as of Q2 2026.

Bridgeway Capital Management held 14,000 shares of Atara Biotherapeutics worth $161K as of Q2 2026.
Bridgeway Capital Management sold 18,691 Atara Biotherapeutics shares in Q2 2026, an estimated $149K.
Atara Biotherapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #1097 holding.
Bridgeway Capital Management first reported a position in Atara Biotherapeutics in Q2 2024 and has held it in 9 quarters since.
Bridgeway Capital Management's Atara Biotherapeutics position peaked at $591K in Q4 2025.
36 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.